CLOs on the Move

Delcath

www.delcath.com

 
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company`s proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In the United States, the PHP system is being developed under the tradename HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZATO, and is considered a combination drug and device product regulated by the United States Food and Drug Administration (FDA).
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.delcath.com
  • 1633 Broadway 22nd Floor, Suite C
    New York, NY USA 10019
  • Phone: 212.489.2100

Executives

Name Title Contact Details
David Hoffman
 Chief Compliance Officer, General Counsel and Corporate Secretary Profile

Similar Companies

QRxPharma Limited

QRxPharma Limited is a Bedminster, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bloodworth Wholesale

Bloodworth Wholesale is a Tifton, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The Buckeye Ranch

Restoring hope and providing healing services for children and families in Central and Southwestern Ohio - from mental health treatment to foster care.

Edesa Biotech Incorporated

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.

Clinglobal